BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24659160)

  • 1. The effects of high fat, low carbohydrate and low fat, high carbohydrate diets on tumor necrosis factor superfamily proteins and proinflammatory cytokines in C57BL/6 mice.
    Sirjani M; Taleban FA; Hekmatdoost A; Amiri Z; Pellizzon M; Hedayati M; Bidad K; Shokouhi Shoormasti R; Pourpak Z
    Iran J Allergy Asthma Immunol; 2014 Aug; 13(4):247-55. PubMed ID: 24659160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
    Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.
    Bai P; Sun Y; Jin J; Hou J; Li R; Zhang Q; Wang Y
    Respir Res; 2011 Dec; 12(1):157. PubMed ID: 22176920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.
    Garlet GP; Cardoso CR; Silva TA; Ferreira BR; Avila-Campos MJ; Cunha FQ; Silva JS
    Oral Microbiol Immunol; 2006 Feb; 21(1):12-20. PubMed ID: 16390336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures.
    Giganti MG; Liuni F; Celi M; Gasbarra E; Zenobi R; Tresoldi I; Modesti A; Bei R; Tarantino U
    J Biol Regul Homeost Agents; 2012; 26(4):671-80. PubMed ID: 23241117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
    Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
    Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.
    Lee JS; Ryu CH; Moon NH; Kim SJ; Park SY; Suh KT
    Arch Orthop Trauma Surg; 2009 May; 129(5):711-8. PubMed ID: 18427820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles.
    Masui T; Sakano S; Hasegawa Y; Warashina H; Ishiguro N
    Biomaterials; 2005 May; 26(14):1695-702. PubMed ID: 15576143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
    Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
    Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
    Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
    Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
    J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.